neuropeptide w23(human)

Neuropeptide SF (human) aceate is a neuropeptide that augmented paraventricular CRH release and increased ACTH and corticosterone levels in the plasma.

Neuropeptide AF (human) acetate (Neuropeptide AF (human) acetate (192387-38-5 Free base)) is an anti-opioid neuropeptide, a Neuropeptide AF (human) derivative, which regulates adipocyte metabolism.

Neuropeptide Y (29-64), amide, human acetate is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.

Neuropeptide W-23(human) (NPW-23) is an endogenous ligand for NPBW1 and NPBW2.

'(Des-Bromo)-Neuropeptide B (1-23) (human)' is an agonist for orphan G-protein-coupled receptors, exhibiting a K i of 1.2 nM for GPR7 (NPBW1) and 341 nM for GPR8 (NPBW2) respectively [1].

[D-Arg25]-Neuropeptide Y (human) ([D-Arg25] NPY), a Y1 receptor selective agonist, plays a role in Alzheimer's disease (AD) and safeguards rat cortical neurons from β-Amyloid toxicity [1].

Neuropeptide W-23 (human) (NPW-23) TFA, representing the active form of Neuropeptide W, functions as an endogenous agonist for both NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1].

Neuropeptide AF (93-110), Human is an endogenous antiopioid peptide.

Biotinyl-neuropeptide W-23 (human) is a biotinylated form of neuropeptide W-23 (human), which functions as an agonist for the NPBW1 (GPR7) and NPBW2 (GPR8) receptors [1] [2].

Neuropeptide Y (3-36) (human, rat) is a metabolite of neuropeptide Y (NPY) generated by dipeptidyl peptidase-4 (DPP4). Known as a selective Y2 receptor agonist, Neuropeptide Y (3-36) (human, rat) effectively reduces the release of norepinephrine via the Y2 receptor[1][2].

Neuropeptide Y (29-64), amide, human is a biologically active 36-amino acid peptide.

High affinity neuropeptide Y Y1 receptor agonist (Ki = 0.39 nM). Also shows affinity for Y4 and Y5 receptors.

Neuropeptide SF (human) considerably increases the amplitude of the sustained current of heterologously expressed ASIC3 (12-fold vs. 19- and nine-fold for FMRFamide and NPFF, respectively) with an EC50 of ~50 μM.

FibrinopeptideB,human is a 14-amino acid polypeptide released from the amino terminus of the fibrinogen segment.

Neuropeptide Y (1-24) (human) is a neuropeptide that inhibits the electrically stimulated twitch response in rat vas deferens and activates neurons in the rat CA3 region of the dorsal hippocampus in vivo following N-methyl-D-aspartate (NMDA) induction [1] [2].

Neuropeptide Y (13-36), amide, human is a neuropeptide Y receptor agonist.

Neuropeptide Y (NPY) (3-36) is a C-terminal fragment of NPY, a neuropeptide involved in controlling appetite, blood pressure, cardiac contractility, and intestinal secretion. NPY (3-36) is an endogenous peptide produced by cleavage of NPY by dipeptidyl peptidase 4 (DPP-4). It binds selectively to the NPY receptor Y2 (Ki = 0.41 nM in CHP 234 cells) over the Y1 receptor, where it does not bind at concentrations up to 1 μM. NPY (3-36) (0.1 nM) increases migration of human umbilical vein endothelial cells (HUVECs) by 80% after 12 hours in an in vitro wound closure assay. NPY (3-36) corresponds to residues 3-36 of the human and rat protein sequence.

[Leu31,Pro34]-Neuropeptide Y(human,rat) TFA acts as a specific agonist for the neuropeptide Y Y1 receptor, while also activating receptors Y4 and Y5. This compound is known to elevate blood pressure in anesthetized rats and enhance food intake [1] [2].

Neuropeptide Y (29-64), amide, human (TFA) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.It is showed that Neuropeptide Y (29-64), amide, human (TFA) is able to protect cortical neurons from Aβ25-35 t

Neuropeptide S human (TFA) is a potent endogenous neuropeptide S receptor agonist (EC50=9.4 nM).

[Tyr0] Gastric Inhibitory Peptide (23-42), human, functions as a glucose-dependent insulinotropic polypeptide (GIP) and exhibits dual activity: it modestly inhibits gastric acid secretion while simultaneously enhancing insulin secretion. This characteristic makes it applicable in research related to diabetes and obesity [1] [2].

Potent endogenous neuropeptide S receptor agonist (EC50 = 9.4 nM). Increases locomotor activity and wakefulness in mice. Also reduces anxiety-like behavior in mice.

Neuropeptide Y (human) TFA, a compound implicated in Alzheimer's disease (AD), exhibits protective effects against β-Amyloid toxicity in rat cortical neurons.